Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
de PANDA trial
2024-519075-26-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, capecitabine, oxaliplatin and docetaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Safety. Planned start Nov 2024; status: authorised.
02
Drugs
atezolizumabcapecitabineoxaliplatindocetaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-519075-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519075-26-00.